A Phase 2 Study of Itraconazole in Castrate-resistant Prostate Cancer Post-chemotherapy
This study evaluates if itraconazole causes a reduction in the serum levels of prostate-specific antigen (PSA) in male subjects with castration-resistant prostate cancer (CRPC).
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : Itraconazole
Phase: Phase 2
Ages Eligible For Study: